LPCN vs. BIOR, UBX, ACST, FBRX, ITRM, APRE, ONCT, QLI, LUMO, and ENLV
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Biora Therapeutics (BIOR), Unity Biotechnology (UBX), Acasti Pharma (ACST), Forte Biosciences (FBRX), Iterum Therapeutics (ITRM), Aprea Therapeutics (APRE), Oncternal Therapeutics (ONCT), Qilian International Holding Group (QLI), Lumos Pharma (LUMO), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.
Biora Therapeutics (NASDAQ:BIOR) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
In the previous week, Lipocine had 4 more articles in the media than Biora Therapeutics. MarketBeat recorded 7 mentions for Lipocine and 3 mentions for Biora Therapeutics. Lipocine's average media sentiment score of 0.75 beat Biora Therapeutics' score of 0.66 indicating that Biora Therapeutics is being referred to more favorably in the media.
Lipocine has higher revenue and earnings than Biora Therapeutics. Lipocine is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lipocine's return on equity of 0.00% beat Biora Therapeutics' return on equity.
Biora Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
Lipocine received 339 more outperform votes than Biora Therapeutics when rated by MarketBeat users. Likewise, 70.14% of users gave Lipocine an outperform vote while only 66.67% of users gave Biora Therapeutics an outperform vote.
43.7% of Biora Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 51.0% of Biora Therapeutics shares are held by company insiders. Comparatively, 6.1% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Biora Therapeutics and Lipocine tied by winning 7 of the 14 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
